Perrigo Acquires Assets of CanAm Care for $36 Million
- CanAm Care expands Perrigo's diabetes care product offering
- All cash transaction with a purchase price of $36 million
- CanAm Care expected to generate approximately $40 million in sales during calendar year 2012
ALLEGAN, Mich., Jan. 9, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has signed a definitive agreement to acquire substantially all of the assets of CanAm Care, a privately-held, Alpharetta, Georgia-based distributor of diabetes care products for approximately $36 million in cash. The acquisition is expected to be immediately accretive to adjusted earnings per share.
The assets acquired from CanAm Care include: Dex4® hypoglycemia products (tabs, liquids and gels), insulin delivery syringes and pen needles, lancing, wound care, and compression stockings. These store brand products will compete in a U.S. diabetes healthcare market opportunity estimated at over $1.5 billion in annual sales.
Perrigo Chairman and CEO Joseph C. Papa stated, "This acquisition, alongside the store brand glucose monitoring meters and strips powered by ONsync™ launched in 2011 with AgaMatrix, showcases our continued commitment to providing a comprehensive line of quality, affordable healthcare to the growing diabetes community."
Added Mr. Papa, "The Center for Disease Control estimates that one in three Americans will develop diabetes in their lifetime. Given the strong patient demand for high quality and value in the overall diabetes care market, we are very pleased to have completed this deal with CanAm Care. Perrigo will be the only full-line store brand supplier to our retail customers in the over-the-counter diabetes care market with this combined portfolio."
Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).
Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Perrigo Company
More by this Source
Perrigo Reports Record Revenue and Adjusted Earnings
May 07, 2013, 07:43 ET
Perrigo Company To Release Third Quarter Fiscal Year 2013 Results On May 7, 2013
Apr 23, 2013, 14:19 ET
Perrigo Company Closes Acquisition Of Companion Animal Health Company, Velcera, Inc.
Apr 01, 2013, 09:17 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.